| |
Miles,
Just had to comment on that post...
First, with biotech's most bet on potential profits not past. If you read my last few posts I have also stressed that we need numbers. I have said before that fourth quarter and the first of next year will prove to be the time when CMTR must step up to the plate... or they will strike out. I haven't checked on the institutional selling, but I'm, sure you saw how the stock reacted on the small news that was released last week. Also, thier ar only two competitors for the at home HIV test. This market, and I'm going to quote from business week, has a market anywhere around "200 million+". With three players, if CMTR captures only 20% of these sales that would be for all of the math majors out there....=20 million. If this company had 20 mil in sales it is way under vaulued with a market cap of only about 15-20 million (dependingon the time of day). The Cholestrol home test... Who else do you know who makes them?? The HpCheck test for H. pylori.... We most definetly IMO have the best distribution. What other distribution chanell would you want besides Astra-Merck????
Finally, I believe that the lack of information on this company is a hindrince but it serves as one of the reasons why the stock is so cheap. The last point I will make is to why IMO the stock has been falling off steadily. It IMO is not because institutions are selling but because of the delay on FDA approval. A couple things can account for this delay, but is it possible that the recent departure of the head of the FDA effected it? maybe.
As Always
Art
One Last Note: Miles-Nice resume with alot of experience. If you have to sell to take a tax loss-so be it. But, I would not rule out buying back after January 1 st. |
|
